{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:44:16Z","timestamp":1760060656518,"version":"build-2065373602"},"reference-count":24,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: Budesonide is a corticosteroid with low systemic bioavailability, commonly used for localized treatment in inflammatory bowel disease (IBD). While its short-term safety is well established, data on long-term effects\u2014particularly regarding bone mineral density (BMD)\u2014are limited. This study assessed the impact of prolonged oral budesonide use on BMD and related adverse events (AEs) in IBD patients. Methods: We retrospectively reviewed IBD patients treated with budesonide for \u226524 months who underwent baseline and follow-up DEXA scans. A matched control group with no history of budesonide use was selected. Clinical and biochemical data, along with DEXA scans, were collected. Changes in BMD of the femur and lumbar spine and BMD status (osteoporosis\/osteopenia) were compared between the groups. Results: A total of 52 budesonide-treated patients (6 with ulcerative colitis and 46 with Crohn\u2019s disease) and 52 matched controls were included. The mean disease duration of the budesonide group and the control group was 8.8 years and 9 years, respectively. Mean budesonide treatment duration was 46.1 \u00b1 15.4 months (range: 25\u201394). No significant differences were observed between the control and treatment groups when the last BMD status was compared with the initial assessment. While femoral BMD remained stable in the budesonide group, it significantly declined in the control group (p = 0.019). L1-L4 BMD improved in the budesonide group (p = 0.002). The osteoporosis rate remained unchanged (OR: 0.136, 95% CI: 0.007\u20132.73, p = 0.19), while osteopenia decreased, favoring the budesonide group (OR: 0.197, 95% CI: 0.038\u20131.018, p = 0.05). No fragility fractures or systemic AEs occurred during follow-up. Conclusions: Long-term oral budesonide use in IBD appears safe with respect to BMD and is not associated with an increased risk of osteoporosis, osteopenia, or previously unrecognized AEs, even with treatment durations of up to four years. The slightly favorable outcome of BMD in IBD patients treated with budesonide needs further verification.<\/jats:p>","DOI":"10.3390\/diagnostics15172271","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T10:29:07Z","timestamp":1757327347000},"page":"2271","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Oral Budesonide Use in Inflammatory Bowel Disease: Effects on Bone Mineral Density and Late-Onset Adverse Events"],"prefix":"10.3390","volume":"15","author":[{"given":"Tugce","family":"Eskazan","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oguz Kagan","family":"Bakkaloglu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6803-4977","authenticated-orcid":false,"given":"Emre","family":"Durcan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atilla","family":"Akpinar","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enes Ali","family":"Kurt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugur","family":"Onal","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf Ziya","family":"Erzin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8385-9253","authenticated-orcid":false,"given":"Ali Ibrahim","family":"Hatemi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aykut Ferhat","family":"Celik","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/jgh.14151","article-title":"Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician","volume":"33","author":"Miehlke","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1365-2036.2003.01386.x","article-title":"Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn\u2019s disease","volume":"17","author":"Lundin","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Brattsand, R., and Selroos, O. (2024). Budesonide Attains Its Wide Clinical Profile by Alternative Kinetics. Pharmaceuticals, 17.","DOI":"10.3390\/ph17040503"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lima, C.A., Lyra, A.C., Mendes, C.M.C., Lopes, M., Coqueiro, F., Rocha, R., and Santana, G. (2017). Bone mineral density and inflammatory bowel disease severity. Braz. J. Med. Biol. Res., 50.","DOI":"10.1590\/1414-431x20176374"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1007\/s00198-018-4586-6","article-title":"Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis","volume":"29","author":"Szafors","year":"2018","journal-title":"Osteoporos. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.3748\/wjg.v26.i35.5362","article-title":"Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease","volume":"26","author":"Lo","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00198-019-05234-w","article-title":"Perspective on skeletal health in inflammatory bowel disease","volume":"31","author":"Bravenboer","year":"2020","journal-title":"Osteoporos. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1074-7613(03)00326-1","article-title":"Colonic dendritic cells, intestinal inflammation and T cell-mediated bone destruction are modulated by recombinant osteoprotogerin","volume":"19","author":"Ashcroft","year":"2003","journal-title":"Immunity"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11914-012-0104-5","article-title":"Pathways for bone loss in inflammatory disease","volume":"10","author":"Braun","year":"2012","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ratajczak, A.E., Rychter, A.M., Zawada, A., Dobrowolska, A., and Krela-Ka\u017amierczak, I. (2020). Nutrients in the Prevention of Osteoporosis in Patients with Inflammatory Bowel Diseases. Nutrients, 12.","DOI":"10.3390\/nu12061702"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tem.2017.10.010","article-title":"Therapeutic Mechanisms of Glucocorticoids","volume":"29","author":"Vandewalle","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_12","unstructured":"Eskazan, T., Durcan, E., Bakkaloglu, O.K., Kurt, E.A., Onal, U., Hatemi, \u0130., Erzin, Y.Z., and Celik, A.F. (2024, January 24\u201327). Is the long-term Budesonide use have any influence on Bone Mineral Density in Inflammatory Bowel Diseases?. Proceedings of the ECCO Congress 2024, Stockholm, Sweden."},{"key":"ref_13","unstructured":"Krugh, M., and Langaker, M.D. (2024). Dual-Energy X-Ray Absorptiometry. StatPearls, StatPearls Publishing."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s41043-025-00946-8","article-title":"Prevalence of osteoporosis in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"44","author":"Emadian","year":"2025","journal-title":"J. Health Popul. Nutr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/ncpgasthep0169","article-title":"Therapy insight: Osteoporosis in inflammatory bowel disease--advances and retreats","volume":"2","author":"Bernstein","year":"2005","journal-title":"Nat. Clin. Pr. Gastroenterol. Hepatol."},{"key":"ref_16","first-page":"CD000296","article-title":"Budesonide for induction of remission in Crohn\u2019s disease","volume":"2015","author":"Rezaie","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.gastrohep.2018.05.013","article-title":"Reviewing the therapeutic role of budesonide in Crohn\u2019s disease. Revisando el papel terap\u00e9utico de la budesonida en la enfermedad de Crohn","volume":"41","author":"Clofent","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_18","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research (2025, June 15). Clinical Pharmacology and Biopharmaceutics Review of Uceris (Budesonide MMX 9 mg) Tablets, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/203634Orig1s000ClinPharmR.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17562848231177151","DOI":"10.1177\/17562848231177151","article-title":"Microscopic colitis is a risk factor for low bone density: A systematic review and meta-analysis","volume":"16","author":"Rancz","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/00325481.2018.1441579","article-title":"Risk of osteoporosis in microscopic colitis","volume":"130","author":"Wildt","year":"2018","journal-title":"Postgrad Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/apt.15648","article-title":"Long-term oral budesonide treatment and risk of osteoporotic fractures in patients with microscopic colitis","volume":"51","author":"Reilev","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/ibd\/izad178","article-title":"Effectiveness and Safety Profile of Budesonide Maintenance in Microscopic Colitis: A Systematic Review and Meta-Analysis","volume":"30","author":"Tome","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1572-0241.2002.05609.x","article-title":"Bone mineral density in Crohn\u2019s disease: A longitudinal study of budesonide, prednisone, and nonsteroid therapy","volume":"97","author":"Cino","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1542-3565(04)00662-7","article-title":"Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn\u2019s disease","volume":"3","author":"Schoon","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/17\/2271\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:41:50Z","timestamp":1760035310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/17\/2271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":24,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["diagnostics15172271"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15172271","relation":{},"ISSN":["2075-4418"],"issn-type":[{"type":"electronic","value":"2075-4418"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}